Pricey Pradaxa aces cost-effectiveness study

When is an $8-a-day drug a bargain compared with one that costs just a dollar? When the expensive drug is Boehringer Ingelheim's new blood thinner Pradaxa, according to a study by Stanford researchers. Report

Suggested Articles

Novavax sign
Manufacturing

Novavax scores $60M Department of Defense deal for COVID-19 shot

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

by Eric Sagonowsky
White House
Vaccines

Experts question why some vaccines were left out of 'Warp Speed'

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

by Eric Sagonowsky
Syringe injection vaccine needle
Manufacturing

Inovio sues manufacturing partner over COVID-19 shot scale-up

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.

by Kyle Blankenship